Altimmune(ALT.US)

Last Updated 19:00:00 ET
longbridge loading

Altimmune | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0

Earnings Watch·
US
ALT
+3.90%
Earnings Watch·
US
ALT
+3.90%

Altimmune Q1 2026 Earnings Call: Complete Transcript

benzinga_article·
US
ALT
+3.90%
US
FBT
+0.69%
US
IBB
+0.68%
benzinga_article·
US
ALT
+3.90%
US
FBT
+0.69%
US
IBB
+0.68%

Altimmune | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0

Earnings Watch·
US
ALT
+3.90%
Earnings Watch·
US
ALT
+3.90%

Altimmune Announces First Quarter 2026 Financial Results and Business Update | ALT Stock News

StockTitan·
US
ALT
+3.90%
US
IBBQ
+0.82%
US
VHT
+0.64%
StockTitan·
US
ALT
+3.90%
US
IBBQ
+0.82%
US
VHT
+0.64%

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 | ALT Stock News

StockTitan·
US
ALT
+3.90%
US
IBBQ
+0.82%
US
VHT
+0.64%
StockTitan·
US
ALT
+3.90%
US
IBBQ
+0.82%
US
VHT
+0.64%

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Fidelity·
US
ALT
+3.90%
US
PBE
+0.35%
US
ARKG
+3.35%
Fidelity·
US
ALT
+3.90%
US
PBE
+0.35%
US
ARKG
+3.35%

Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from Analysts

Market Beat·
US
ALT
+3.90%
US
SBIO
+1.84%
US
ARKG
+3.35%
Market Beat·
US
ALT
+3.90%
US
SBIO
+1.84%
US
ARKG
+3.35%

Altimmune Raises ~$211 Million in Stock-and-Warrant Offering Led by Leerink and Barclays

TradingView·
US
ALT
+3.90%
US
XLV
+0.69%
US
XBI
+0.81%
TradingView·
US
ALT
+3.90%
US
XLV
+0.69%
US
XBI
+0.81%

Altimmune shares are trading lower after the company announced the pricing of its $225 million oversubscribed public offering of 64.25 million shares at $3.00 per share.

benzinga_article·
US
ALT
+3.90%
US
PBE
+0.35%
US
SBIO
+1.84%
benzinga_article·
US
ALT
+3.90%
US
PBE
+0.35%
US
SBIO
+1.84%
© 2026 Longbridge｜Disclaimer